



Exploring the Human Genome with J. Craig Venter, Ph.D.

ROTH CONFERENCE

MARCH 13-16 • 2016



Sunday, March 13, 2016 | 3:15pm - 4:15pm
Pacific Promenade Ballroom



Keynote Presentation

Please join ROTH Capital Partners for a special keynote presentation by J. Craig Venter, Ph.D. discussing the human genome.

Keynote Speaker: J. Craig Venter, Ph.D.

J. Craig Venter, Ph.D., is regarded as one of the leading scientists of the 21st century for his numerous invaluable contributions to genomic research. He is the co-founder, executive chairman, and CEO of Human Longevity, Inc., a San Diego-based genomics and cell therapy-based diagnostic and therapeutic company focused on extending the healthy, high performance human life span. He is also the founder, chairman, and CEO of the J. Craig Venter Institute (JCVI), a non-profit, research organization dedicated to human, microbial, plant, synthetic and environmental genomic research, and the exploration of social and ethical issues in genomics.

Dr. Venter is also co-founder, executive chairman and co-chief scientist of Synthetic Genomics Inc (SGI), a privately held company focused on developing products and solutions using synthetic genomics technologies.

In 1984, Dr. Venter moved to the National Institutes of Health campus where he developed Expressed Sequence Tags or ESTs, a revolutionary new strategy for rapid gene discovery. In 1992 Dr. Venter founded The Institute for Genomic Research (TIGR, now part of JCVI), a not-for-profit research institute, where in 1995 he and his team decoded the genome of the first free-living organism, the bacterium *Haemophilus influenzae*, using his new whole genome shotgun technique.

In 1998, Dr. Venter founded Celera Genomics to sequence the human genome using new tools and techniques he and his team developed. This research culminated with the February 2001 publication of the human genome in the journal, *Science*. He and his team at Celera also sequenced the fruit fly, mouse and rat genomes. Dr. Venter and his team at JCVI continue to blaze new trails in genomics. They have sequenced and analyzed hundreds of genomes, and have published numerous important papers covering such areas as environmental genomics, the first complete diploid human genome, and the groundbreaking advance in creating the first self-replicating bacterial cell constructed entirely with synthetic DNA.

(Source: J. Craig Venter Institute Website | 2.4.16)

Introduced By: Michael J. Lerner, Partner - Lowenstein Sandler

Michael J. Lerner, Chair of Lowenstein Sandler's Life Sciences Group, has been advising pharmaceutical, life sciences and healthcare companies on key strategic matters for over 30 years, both as in house counsel and outside legal and business advisor. He also is a member of the firm's Corporate Department and Tech Group.

(Source: Lowenstein Sandler Website | 2.9.16)

By invitation only.

Please email registration@roth.com or contact your ROTH representative at 800.933.6830.

This is not an offer or solicitation of the securities herein.



Lowenstein Sandler